Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
316 studies found for:    cd13
Show Display Options
Rank Status Study
1 Unknown  Combined Inhibition of Dipeptidyl Peptidase IV (DPIV/CD26) and Aminopeptidase N (APN/CD13) in the Treatment of Psoriasis
Condition: Psoriasis
Intervention: Drug: IP10.C8
2 Completed Nonmyeloablative Stem Cell Transplantation With CD8-depleted or Unmanipulated Peripheral Blood Stem Cells (PBSC)
Condition: Hematologic Malignancies
Interventions: Procedure: Unmanipulated PBSC after nonmyeloablative conditioning;   Procedure: CD8-depleted PBSC after nonmyeloablative conditioning
3 Recruiting Iatrogenic Chronotropic Incompetence and Exercise Tolerance in Heart Failure
Condition: Chronic Heart Failure
Interventions: Drug: ivabradine;   Drug: Placebo;   Other: Exercise
4 Terminated Tc-99m Renography and Cisplatin-induced Nephrotoxicity
Conditions: Cancer;   Drug Toxicity;   Kidney Failure
Intervention:
5 Enrolling by invitation Stem Cell Transplantation for the Treatment of Knee Osteoarthritis
Condition: Knee Osteoarthritis
Intervention: Biological: Autologous Stem Cell Transplantation
6 Terminated Stem Cell Transplantation in Ocular Lesions of Behcet's Disease
Conditions: Retinitis;   Behcet's Syndrome
Intervention: Biological: Autologous Stem Cell Transplantation
7 Not yet recruiting Genetically Modified T-cells in Treating Patients With Recurrent or Refractory Malignant Glioma
Conditions: Adult Anaplastic Astrocytoma;   Adult Anaplastic Ependymoma;   Adult Anaplastic Oligodendroglioma;   Adult Brain Stem Glioma;   Adult Ependymoblastoma;   Adult Giant Cell Glioblastoma;   Adult Glioblastoma;   Adult Gliosarcoma;   Adult Mixed Glioma;   Adult Pineal Gland Astrocytoma;   Recurrent Adult Brain Tumor
Interventions: Biological: IL13Rα2-specific, hinge-optimized, 41BB-costimulatory CAR/truncated CD19-expressing T lymphocytes;   Other: laboratory biomarker analysis;   Other: quality-of-life assessment
8 Terminated Yttrium Y 90 Anti-CD45 Monoclonal Antibody AHN-12 in Treating Patients With Advanced Leukemia
Conditions: Leukemia;   Myelodysplastic Syndromes
Interventions: Biological: anti-CD45 monoclonal antibody AHN-12;   Radiation: yttrium Y 90 anti-CD45 monoclonal antibody AHN-12
9 Completed Phase I Study of Cellular Immunotherapy for Recurrent/Refractory Malignant Glioma Using Intratumoral Infusions of GRm13Z40-2, An Allogeneic CD8+ Cytolitic T-Cell Line Genetically Modified to Express the IL 13-Zetakine and HyTK and to be Resistant to Glucocorticoids, in Combination With Interleukin-2
Conditions: Anaplastic Astrocytoma;   Anaplastic Ependymoma;   Anaplastic Meningioma;   Anaplastic Oligodendroglioma;   Brain Stem Glioma;   Ependymoblastoma;   Giant Cell Glioblastoma;   Glioblastoma;   Gliosarcoma;   Grade III Meningioma;   Meningeal Hemangiopericytoma;   Mixed Glioma;   Pineal Gland Astrocytoma;   Brain Tumor
Interventions: Biological: therapeutic allogeneic lymphocytes;   Biological: aldesleukin;   Other: laboratory biomarker analysis;   Procedure: positron emission tomography
10 Completed A Study to Assess AFM13 in Patients With Hodgkin Lymphoma
Condition: Hodgkin Lymphoma
Intervention: Drug: AFM 13
11 Recruiting Yttrium Y 90 Anti-CD45 Monoclonal Antibody BC8 Followed by Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome
Conditions: Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable;   Previously Treated Myelodysplastic Syndromes;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Refractory Anemia With Excess Blasts;   Secondary Acute Myeloid Leukemia
Interventions: Radiation: yttrium Y 90 anti-CD45 monoclonal antibody BC8;   Biological: indium In 111 anti-CD45 monoclonal antibody BC8;   Drug: fludarabine phosphate;   Drug: cyclosporine;   Drug: mycophenolate mofetil;   Radiation: total-body irradiation;   Procedure: peripheral blood stem cell transplantation;   Procedure: allogeneic bone marrow transplantation;   Procedure: allogeneic hematopoietic stem cell transplantation;   Other: laboratory biomarker analysis;   Other: pharmacological study
12 Active, not recruiting Safety and Efficacy of Monthly Replacement Therapy With Recombinant Factor XIII (rFXIII) in Paediatric Subjects With Congenital Factor XIII A-subunit Deficiency
Conditions: Congenital Bleeding Disorder;   Congenital FXIII Deficiency
Intervention: Drug: catridecacog
13 Not yet recruiting Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Conditions: Adult Acute Megakaryoblastic Leukemia (M7);   Adult Acute Minimally Differentiated Myeloid Leukemia (M0);   Adult Acute Monoblastic Leukemia (M5a);   Adult Acute Monocytic Leukemia (M5b);   Adult Acute Myeloblastic Leukemia With Maturation (M2);   Adult Acute Myeloblastic Leukemia Without Maturation (M1);   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Adult Acute Myelomonocytic Leukemia (M4);   Adult Erythroleukemia (M6a);   Adult Pure Erythroid Leukemia (M6b);   Recurrent Adult Acute Myeloid Leukemia
Interventions: Drug: cyclophosphamide;   Biological: anti CD123-CAR/CD28-costimulatory, retroviral vector-transduced autologous T lymphocytes;   Other: laboratory biomarker analysis
14 Recruiting GP2013 in Japanese Patients With CD20 Positive Low Tumor Burden Indolent B-cell Non-Hodgkin's Lymphoma
Condition: Indolent B-cell Non-Hodgkin's Lymphoma
Intervention: Drug: GP2013
15 Active, not recruiting Multisite Controlled Trial of Cocaine Vaccine
Condition: Cocaine Dependence
Interventions: Drug: TA-CD Vaccination;   Other: Placebo Injection
16 Completed
Has Results
HuMax-CD20 i(Ofatumumab) n Follicular Lymphoma (FL) Patients Refractory to Rituximab
Condition: Lymphoma, Follicular
Intervention: Drug: Ofatumumab
17 Terminated
Has Results
Long-term Efficacy and Safety of Repeated Ofatumumab Treatment Courses in RA Patients Who Previously Received Ofatumumab or Placebo in Trial Hx-CD20-403
Condition: Arthritis, Rheumatoid
Intervention: Drug: ofatumumab
18 Recruiting Donor Peripheral Stem Cell Transplant in Treating Patients With Hematolymphoid Malignancies
Conditions: Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Cutaneous B-cell Non-Hodgkin Lymphoma;   Extranodal Marginal Zone B-cell Lymphoma;   Hepatosplenic T-cell Lymphoma;   Intraocular Lymphoma;   Nodal Marginal Zone B-cell Lymphoma;   Peripheral T-cell Lymphoma;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Adult T-cell Leukemia/Lymphoma;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Small Lymphocytic Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Relapsing Chronic Myelogenous Leukemia;   Splenic Marginal Zone Lymphoma;   Waldenstrom Macroglobulinemia
Intervention: Biological: therapeutic allogeneic lymphocytes
19 Terminated Donor T Cells in Treating Patients With High-Risk Hematologic Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant
Conditions: Graft Versus Host Disease;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes
Interventions: Biological: CD4+CD25+ regulatory T cells;   Procedure: allogeneic hematopoietic stem cell transplantation
20 Recruiting Autologous T-Lymphocytes Genetically Targeted to the B-Cell Specific Antigen CD19 in Pediatric and Young Adult Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia
Condition: Relapsed B-Cell Acute Lymphoblastic Leukemia
Interventions: Procedure: leukapheresis or collection of PBMCs;   Drug: cyclophosphamide;   Biological: modified T cells

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years